Fuyuki Minagawa
Yokohama, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications
Pretreatment body mass index affects achievement of target blood pressure with sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus and chronic kidney disease.
Journal: Hypertension research : official journal of the Japanese Society of Hypertension
Published: August 02, 2023
Comparison of renal outcomes between sodium glucose co-transporter 2 inhibitors and glucagon-like peptide 1 receptor agonists.
Journal: Diabetes research and clinical practice
Published: November 04, 2021
Retrospective Analysis of the Renoprotective Effects of Long-Term Use of Six Types of Sodium-Glucose Cotransporter 2 Inhibitors in Japanese Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease.
Journal: Diabetes technology & therapeutics
Published: July 30, 2020
Blood pressure after treatment with sodium-glucose cotransporter 2 inhibitors influences renal composite outcome: Analysis using propensity score-matched models.
Journal: Journal of diabetes investigation
Published: April 20, 2020
A Study of Seasonal Variation in the Effect of Add-On Sitagliptin on Blood Glucose Control in Insulin-Treated Patients With Type 2 Diabetes.
Journal: Journal of clinical medicine research
Published: January 29, 2020
Effects of ipragliflozin on the development and progression of kidney disease in patients with type 2 diabetes: An analysis from a multicenter prospective intervention study.
Journal: Journal of diabetes investigation
Published: December 06, 2019
The effect of long-term past glycemic control on executive function among patients with type 2 diabetes mellitus.
Journal: Diabetology international
Published: June 14, 2019
Efficacy and Safety of Adding Sitagliptin in Type 2 Diabetes Patients on Insulin: Age-Stratified Comparison at One Year in the ASSIST-K Study.
Journal: Journal of clinical medicine research
Published: November 02, 2018
Effectiveness of Ipragliflozin for Reducing Hemoglobin A1c in Patients With a Shorter Type 2 Diabetes Duration: Interim Report of the ASSIGN-K Study.
Journal: Journal of clinical medicine research
Published: May 25, 2017
Ipragliflozin Improves Glycemic Control and Decreases Body Fat in Patients With Type 2 Diabetes Mellitus.
Journal: Journal of clinical medicine research
Published: April 11, 2017
Association of usual sleep quality and glycemic control in type 2 diabetes in Japanese: A cross sectional study. Sleep and Food Registry in Kanagawa (SOREKA).
Journal: PloS one
Published: March 24, 2017
Correction: Efficacy and Safety of Ipragliflozin in Japanese Patients With Type 2 Diabetes: Interim Outcome of the ASSIGN-K Study.
Journal: Journal of clinical medicine research
Published: January 20, 2016
Last Updated: 09/26/2026